03 October 2022
EMA/667468/2022
EMEA/H/C/002558

Public statement

Glidipion (pioglitazone)

Withdrawal of the marketing authorisation in the European Union

On 19 July 2021, the European Commission withdrew the marketing authorisation for Glidipion (pioglitazone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Actavis Group PTC ehf, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Glidipion was granted marketing authorisation in the EU on 15 March 2012 for treatment of type 2 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016. The product has not been marketed in the EU.

Glidipion is a generic medicine of Actos. There are other generic medicinal products of Actos authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Glidipion will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union